Aug. 17, 2012
/PRNewswire/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) reiterated its research relationship with
and announced that
today issued the following release, which stated, "The Department of Dermatology in the Stanford School of Medicine has had a long-standing research-based relationship with Nu Skin Enterprises. Researchers in the department currently have one on-going study funded by Nu Skin related to the identification of master regulators and epigenetic changes to human skin aging. This research project is funded from a
commitment from Nu Skin and runs through 2014. Since 1999, the company has funded nearly
$5.8 million dollars
in research in the Department of Dermatology.
"At the request of Dr.
, a letter was sent by
to Nu Skin requesting Dr. Kim's name be removed from the company's marketing materials and websites as Dr. Kim is no longer involved with research funded by the company. The company complied with this request. The letter did not recognize, however, the existing research relationship between Nu Skin and
. We regret any misunderstanding that may have occurred as a result."
About Nu Skin Enterprises
Nu Skin Enterprises, Inc. demonstrates its tradition of innovation through its comprehensive anti-aging product portfolio, independent business opportunity and corporate social responsibility initiatives. The company's scientific leadership in both skin care and nutrition has established Nu Skin as a premier anti-aging company, evidenced in its unique ageLOC® science that addresses aging at its source. The company's anti-aging products feature the new ageLOC ® suite of products including the ageLOC® R
nutritional supplement, ageLOC® Galvanic Spa System and ageLOC Galvanic Body Spa™, as well as the ageLOC® Transformation daily skin care system. A global direct selling company, Nu Skin operates in 53 markets worldwide and has nearly 900,000 independent distributors. Nu Skin is traded on the New York Stock Exchange under the symbol "NUS." More information is available at